Teva execs may have zeroed in on their first big revamp move since CEO Erez Vigodman's sudden exit.

Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continue to demonstrate, getting there may…

Novartis is denying a report out of India suggesting it may be looking to retreat from the increasingly competitive market for asthma and COPD drugs and is…

Sanofi is in talks to buy Flexion Therapeutics, a biotech with its lead product awaiting FDA approval, for more than $1 billion, according to a source close to…

Allergan is facing potential fallout from shareholders who say Allergan’s share price has been stung by questionable generics pricing.

The race to snatch up generics maker Stada is heating up—and fast—with multiple players reportedly preparing to jump in, including Chinese drugmakers and,…

The rumors are true: When it comes to biosimilars, Merck KGaA has had enough.

Sanofi is prepping the sale of its European generics unit, according to a new report.

Pfizer, which scooped up Bamboo Therapeutics last year in its aim to be a major player in gene therapies, is now looking at building a gene therapy production…

M&A